May 27, 2020
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease
May 11, 2020
AllianceRx Walgreens Prime studies the use of cyclin-dependent kinase 4/6 inhibitors in breast cancer patients
Apr 16, 2020
Health Canada approves an extended indication for KISQALI® (ribociclib) in combination treatment
Oct 23, 2019
Women living with metastatic breast cancer in British Columbia now have public access to KISQALI®
Sep 29, 2019
Novartis Kisqali® delivers consistently superior overall survival - MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
Sep 19, 2019
Addition of KISQALI® to drug plan in Quebec expands access to treatment for metastatic breast cancer
Jun 11, 2019
Neuroendocrine Tumor Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Jun 01, 2019
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
Nov 02, 2018
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
Jul 18, 2018
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
Jun 03, 2018
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
Jan 03, 2018
Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Nov 14, 2017
Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
Sep 05, 2017
MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor